Search
Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid a...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalCanagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approv...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsEperisone
go.drugbank.com/drugs/DB08992InvestigationalEperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. It i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBisacodyl
go.drugbank.com/drugs/DB09020ApprovedInvestigational[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).
Products: P Lax DrSuvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Categories: Orexin Receptor Antagonists, P-glycoprotein inhibitorsVortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalspecifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesLenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalLenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). … These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as
Categories: Receptor Tyrosine Kinase Inhibitors, P-glycoprotein inhibitorsVilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigationalVilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDifluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnDifluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers